Open Access Letter to Editorknown to be common, but less so than open surgery (39%) [6]. This is comparable to other robotic series. Although some patients had limited follow-up, 6 (33%) were continent and 67% were free of biochemical progression.Many SRALP patients have localised disease recurrence and therefore potentially curable disease [2]. The key to decreased morbidity SRALP outcomes are to have experienced centers and fellowship training, a standardisation of training [2]. The robotic surgery curriculum is welcomed as part of this. These centre have demonstrated the advantages of the robotic platform in the performance of salvage radical prostatectomy. This includes decreased blood loss, short length of stay and improved haptic feedback. This was confirmed with a decreasing positive surgical margin rate with each consecutive group of 50 cases, including pT3 and high-risk patients [7]. The 3-year, 5-year, and 7-year BCR-free survival rates were 79.2%, 75.3%, and 70.2%, respectively [7]. 250 cases have become a landmark for lowest positive surgical margin rates, although, it may take more experience than this to manage SRALP cases [7].Increasingly complex cases can be taken on as the learning curve progress [5]. Very often with salvage cases, significant intra-abdominal adhesions, dense periprostatic inflammation post URP; large prostate gland size and median lobes may alter bladder neck anatomy. This makes for a difficult urethro-vesical anastomosis [5]. This highlights the importance of a having a good robotic pelvic experience, prior to taking on salvage cases.Compared to open and laparoscopic procedures perioperative SRALP outcomes were positive, with low complication rates and estimated blood loss equivocal to open or lap procedures [1]. This demonstrates robotic technology can aid the surgeon in salvage prostatectomy [1]. However, experience and training are key to minimal morbidity [3]. This procedure has significant advantages over open surgery in selected patients and is an excellent alternative to other salvage therapies, and allows a broader spectrum of patients to be treated compared to open surgery [3]. SRALP also offers complete staging of high-risk prostate cancer thereby allowing optimum planning of adjuvant and salvage therapies [8]. However, many high-risk prostate cancers are subsequently downgraded or down staged on final histopathology [8], rendering the patient disease free.